Pharmaceuticals, Biotechnology and Life Sciences
The FDA approved an expanded indication of ViiV Healthcare’s Dovato (dolutegravir/lamivudine), a complete two-drug regimen for virologically suppressed adults with HIV-1 with no history of treatment failure or resistance to Dovato’s components.
ViiV Healthcare Friday said that the US Food and Drug Administration (FDA) has approved Tivicay PD (dolutegravir) tablets for oral suspension, used combined with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in certain young patients.